5 Results for "

Chembridge-5861528

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "Chembridge-5861528" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-15065
CAS No.: 332117-28-9
Purity:  99.76%
Synonyms: TCS 5861528
Chembridge-5861528 (TCS 5861528) is a potent TRPA1 channel antagonist that antagonizes similarly allyl isothiocyanate- and 4-HNE-evoked TRPA1 responses, with IC50 values of 14.3 μM and 18.7 μM, respectively. Chembridge-5861528 shows antihypersensitivity activities .
loading...
    loading...
Cat. No.: HY-P10654
CAS No.: 2861260-80-0
Target:  

TRP Channel

Research Areas:  

Neurological Disease

RhTx is a transient receptor potential vanillin-1 (TRPV1) activator. RhTx can be used to study pain perception .
loading...
    loading...
Cat. No.: HY-P3314
CAS No.: 2251119-65-8
Target:  

Somatostatin Receptor

Research Areas:  

Metabolic Disease

Nendratareotide is a somatostatin analogue .
loading...
    loading...
Cat. No.: HY-P10819
Research Areas:  

Cancer

S9-CMC1 TFA is a covalent peptide lysine-specific demethylase 1 (LSD1) inhibitor with an IC50 value of 2.53 μM. S9-CMC1 TFA specifically recognizes Cys360 in the enzyme-active region. S9-CMC1 TFA inhibits LSD1 activity, increasing H3K4me1 and H3K4me2 levels, leading to G1 cell cycle arrest and apoptosis and inhibiting cell proliferation. S9-CMC1 TFA significantly inhibits tumor growth in A549 xenograft animal models .
loading...
    loading...
Cat. No.: HY-P11408
CAS No.: 349657-39-2
Target:  

Bombesin Receptor

Research Areas:  

Neurological Disease Cancer

[D-Cys6,Asn7,D-Ala11,Cys14]-Bombesin (6-14), a synthetic peptide, is a non-selective bombesin receptor agonist. [D-Cys6,Asn7,D-Ala11,Cys14]-Bombesin (6-14) has preferred pEC50 values of 8.06 for the neurotrophin B bombesin receptor (BB1), 8.69 for the gastrin-releasing peptide bombesin receptor (BB2), and 6.71 for the orphan receptor (BB3). [D-Cys6,Asn7,D-Ala11,Cys14]-Bombesin (6-14) can be used to study diseases related to bombesin receptors, such as cancer and neurological disorders .
loading...
    loading...